Inhibitors of nitric oxide synthase to treat type 1 diabetes
US7396659B2 · kind B2 · utility
9Cited by
20References
36Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 15, 2005 |
| Grant date | Jul 8, 2008 |
| Priority date | — |
| Expiry date | Aug 25, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/99
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating type 1 diabetes in a human in need of such treatment, comprising administering to the human a biologically effective amount of at least one inhibitor of inducible nitric oxide synthase or a pro-inflammatory cytokine, wherein the inhibitor is an inhibitor of HMG-CoA reductase or a pharmaceutically acceptable salt thereof, and the inhibitor specifically inhibits the activity of HMG-CoA reductase.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.